Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R. Brown, Mazyar Shadman, Amanda Gillespie-Twardy et al.|New England Journal of Medicine|2022Cited by 453
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Wojciech Jurczak, Barbara Eichhorst et al.|Journal of Clinical Oncology|2022Cited by 93
Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)Jennifer R. Brown, Mazyar Shadman, Barbara Eichhorst et al.|Blood|2023Cited by 24
CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Jennifer R. Brown, Wojciech Jurczak, Peter Hillmen et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 12
CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL.Mazyar Shadman, Piers Patten, Arnon P. Kater et al.|Journal of Clinical Oncology|2024Cited by 8